Johnson & Johnson is reporting a strong finish to the year, overcoming the disruption of the global pandemic in some parts of its business such as medical device sales.
Net income reached f $1.74 billion, or 65 cents per share in the fourth quarter.
Removing one time charges and costs, the New Brunswick, New Jersey, company’s per share earnings were $1.86, easily surpassing the $1.81 Wall Street was looking for, according to a survey of industry analysts by Zacks Investment Research.
The world’s biggest maker of health care products posted revenue of $22.48 billion also topping analyst projections for $21.62 billion.
Johnson & Johnson expects full-year earnings in the range of $9.40 to $9.60 per share, with revenue in the range of $90.5 billion to $91.7 billion.
Shares are up about 1.5% before the opening bell Tuesday.
A portion of this story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ